Wanbury Share Price Target 2026 Analyst Forecast Bull and Bear Case

Wanbury (NSE: WANBURY) is a API Pharmaceuticals and Formulations company trading at Rs 274.35 with a market capitalisation of Rs 958 crore. Analysts have set the Wanbury share price target at Rs 330 for 2026, based on FY27 earnings projections and sector re-rating potential. According to Ankit Jaiswal, Senior Research Analyst at Univest, the Rs 330 price objective reflects improving fundamentals in the API Pharmaceuticals and Formulations space. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Wanbury Share Price Target 2026: Key Takeaways

• Wanbury share price target 2026: Rs 330 (20% upside from CMP Rs 274.35)
• Bull case: Rs 400 | Bear case: Rs 220
• Ticker: WANBURY | Sector: API Pharmaceuticals and Formulations | MCap: Rs 958 crore
• 52W range: Rs 161.5 to Rs 315.2 | PE: 15x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Wanbury Company Overview

Wanbury (NSE: WANBURY) is a Mumbai-based pharmaceutical company manufacturing active pharmaceutical ingredients including metformin and anti-diabetic APIs along with generic formulations for domestic and global markets. At CMP Rs 274.35 against a 52 week range of Rs 161.5 to Rs 315.2, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 958 crore with trailing PE of 15x. Compared to peers in API pharma like Divi’s Laboratories and Solara Active Pharma Sciences, Wanbury is positioned as a potential re-rating candidate toward the Rs 330 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	WANBURY
Sector	API Pharmaceuticals and Formulations
CMP (2026)	Rs 274.35
52 Week High	Rs 315.2
52 Week Low	Rs 161.5
Market Cap	Rs 958 crore
Trailing PE	15x
12-Month Analyst Target	Rs 330
Bull Case Target	Rs 400
Bear Case Target	Rs 220

Why Is the Wanbury Share Price Target Set at Rs 330 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Wanbury share price target of Rs 330 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Ankit Jaiswal at Univest notes that Q4 FY26 results confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 274.35.

Structural Sector Tailwinds in API Pharmaceuticals and Formulations

The API Pharmaceuticals and Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Wanbury’s position among peers in API pharma like Divi’s Laboratories and Solara Active Pharma Sciences creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 400 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Wanbury’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 330 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Wanbury’s API Pharmaceuticals and Formulations operations, improving the probability of achieving the Rs 330 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Wanbury is positioned as a beneficiary of institutional reallocation toward the Rs 400 bull case over the medium term.

Wanbury Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Wanbury Share Price Target

Near-term support for Wanbury is anchored close to the 52 week low of Rs 161.5. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 274.35.

12-Month Wanbury Share Price Target 2026

The 12-month Wanbury share price target 2026 is Rs 330, implying approximately 20 percent upside from CMP Rs 274.35. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Wanbury Share Price Target: FY27 to FY28

The long term Wanbury share price target for FY27 to FY28 is Rs 400 in the bull case, requiring full earnings delivery, re-rating among peers in API pharma like Divi’s Laboratories and Solara Active Pharma Sciences, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Wanbury in 2026

Bull Case Wanbury Share Price Target: Rs 400

The bull case Wanbury share price target of Rs 400 materialises when FY27 earnings beat analyst estimates, API Pharmaceuticals and Formulations tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 274.35.

Bear Case Wanbury Share Price Target: Rs 220

The bear case Wanbury share price target of Rs 220 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 161.5.

Scenario	Target	Key Conditions
Bull Case	Rs 400	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 330	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 220	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Wanbury 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Wanbury share price target of Rs 330, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 330 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among API Pharmaceuticals and Formulations Peers

Intensifying competition from peers in API pharma like Divi’s Laboratories and Solara Active Pharma Sciences could compress Wanbury’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 330 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Wanbury

Check the Univest Screener for live data

Before considering any investment based on the Wanbury share price target of Rs 330, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on API Pharmaceuticals and Formulations sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Wanbury (NSE: WANBURY) with full regulatory protection. Study the competitive landscape among peers in API pharma like Divi’s Laboratories and Solara Active Pharma Sciences before executing any position.

Plan your entry using the 52 week low of Rs 161.5 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 330 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Wanbury’s live share price and receive daily stock recommendations.

FAQs on Wanbury Share Price Target 2026

What is the Wanbury share price target for 2026?

Ans. The Wanbury share price target 2026 is Rs 330, implying approximately 20 percent upside from CMP Rs 274.35. Bull case is Rs 400, bear case is Rs 220.

What was the Wanbury share price target for 2025?

Ans. The 2025 price objective for Wanbury was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 330, reflecting FY27 growth potential from CMP Rs 274.35.

Is Wanbury a good investment at Rs 274.35?

Ans. At Rs 274.35, Wanbury offers potential upside toward Rs 330 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Wanbury share price target 2026?

Ans. Key risks to the Wanbury share price target of Rs 330 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in API Pharmaceuticals and Formulations. Monitoring quarterly results is essential.

What is the 52 week high and low of Wanbury?

Ans. The 52 week high of Wanbury is Rs 315.2 and the 52 week low is Rs 161.5. At CMP Rs 274.35, the stock offers potential upside toward the Rs 330 price objective.

What are the main growth catalysts for Wanbury in 2026?

Ans. Key catalysts include FY27 PAT recovery, API Pharmaceuticals and Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Wanbury compare to its peers?

Ans. Wanbury operates in API Pharmaceuticals and Formulations alongside peers in API pharma like Divi’s Laboratories and Solara Active Pharma Sciences. At CMP Rs 274.35 with MCap Rs 958 crore, it is a potential re-rating candidate toward the Wanbury share price target of Rs 330 on FY27 delivery.

What is the Wanbury share price target for 2027?

Ans. The long-term Wanbury share price target for FY27 to FY28 is Rs 400 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.